---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-021980"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T20:52:23.237622+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Interpace Biosciences Reports Q3 2025 Revenue of $8.8M, Thyroid Test Volume Up 12% YoY

## Summary
- Q3 2025 revenue $8.8M, up 22% pro forma vs prior year; operating income $1.1M
- Thyroid test volume grew 12% year-over-year to record levels; thyroid revenue $8.8M, up 22%
- Cash collections $10.0M in Q3; days sales outstanding reduced 22%
- Income from continuing operations $1.0M; adjusted EBITDA $1.3M
- Company completed transition to thyroid-only diagnostics; additional debt principal payments made

## SEC filing metadata
- accession: 0001493152-25-021980
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315225021980/0001493152-25-021980-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315225021980/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-021980
- JSON: https://secwatch.observer/filing/0001493152-25-021980.json
- Plain text: https://secwatch.observer/filing/0001493152-25-021980.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.